A rhPDGF‐BB/bovine type I collagen/β‐TCP mixture for the treatment of critically sized non‐union tibial defects: An in vivo study in rabbits

Abstract

AbstractNon‐union during healing of bone fractures affects up to ~5% of patients worldwide. Given the success of recombinant human platelet‐derived growth factor‐B chain homodimer (rhPDGF‐BB) in promoting angiogenesis and bone fusion in the hindfoot and ankle, rhPDGF‐BB combined with bovine type I collagen/β‐TCP matrix (AIBG) could serve as a viable alternative to autografts in the treatment of non‐unions. Defects (~2 mm gaps) were surgically induced in tibiae of skeletally mature New Zealand white rabbits. Animals were allocated to one of four groups—(1) negative control (empty defect, healing for 8 weeks), (2 and 3) acute treatment with AIBG (healing for 4 or 8 weeks), and (4) chronic treatment with AIBG (injection 4 weeks post defect creation and then healing for 8 weeks). Bone formation was analyzed qualitatively and semi‐quantitatively through histology. Samples were imaged using dual‐energy X‐ray absorptiometry and computed tomography for defect visualization and volumetric reconstruction, respectively. Delayed healing or non‐healing was observed in the negative control group, whereas defects treated with AIBG in an acute setting yielded bone formation as early as 4 weeks with bone growth appearing discontinuous. At 8 weeks (acute setting), substantial remodeling was observed with higher degrees of bone organization characterized by appositional bone growth. The chronic healing, experimental, group yielded bone formation and remodeling, with no indication of non‐union after treatment with AIBG. Furthermore, bone growth in the chronic healing group was accompanied by an increased presence of osteons, osteonal canals, and interstitial lamellae. Qualitatively and semiquantitatively, chronic application of AI facilitated complete bridging of the induced non‐union defects, while untreated defects or defects treated acutely with AIBG demonstrated a lack of complete bridging at 8 weeks.